Rivaroxaban and Omeprazole Co-administration Guidelines

Metabolic Pathway Considerations

Omeprazole does not significantly inhibit or induce CYP3A4 or P-glycoprotein (P-gp), the key pathways affecting rivaroxaban levels, according to the American Heart Association, as reported in Circulation: Arrhythmia and Electrophysiology 1
Only strong dual inhibitors of both CYP3A4 and P-gp (such as azole antifungals and HIV protease inhibitors) significantly increase rivaroxaban plasma concentrations by approximately 2.5-fold, as stated by the medical community, and also reported in Praxis Medical Insights: Practical Summaries of Clinical Guidelines, however, the American College of Cardiology recommends considering alternative antifungals or HIV treatments to minimize interactions 2

Exercise caution when combining rivaroxaban with NSAIDs or antiplatelet agents, as these create additive bleeding risk through separate mechanisms, as advised by the American Heart Association, and reported in Circulation: Arrhythmia and Electrophysiology, with a strength of evidence level of high 1
Avoid triple therapy (rivaroxaban + NSAID + antiplatelet agent) as this substantially increases bleeding risk, according to the medical guidelines, as reported in Praxis Medical Insights: Practical Summaries of Clinical Guidelines, with a recommendation grade of strong, however, the American College of Cardiology suggests considering alternative treatments to minimize bleeding risk 3

Do not confuse omeprazole's safety profile with strong CYP3A4/P-gp inhibitors like ketoconazole or ritonavir, which are contraindicated with rivaroxaban, as warned by the medical community, and reported in Circulation: Arrhythmia and Electrophysiology, with a strength of evidence level of high 1